查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1976589

登革熱檢測市場：依檢測方法、技術、最終用戶、產品類型、安裝位置和檢體類型分類－2026-2032年全球預測

Dengue Testing Market by Test Type, Technology, End User, Product Type, Setting, Sample Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，登革熱檢測市場價值將達到 5.5861 億美元，到 2026 年將成長至 5.9901 億美元，到 2032 年將達到 8.5512 億美元，複合年成長率為 6.27%。

主要市場統計數據
基準年 2025 5.5861億美元
預計年份：2026年 5.9901億美元
預測年份 2032 8.5512億美元
複合年成長率 (%) 6.27%

本文將介紹登革熱診斷的現狀，包括不斷發展的檢測方法、實施挑戰以及在醫療環境中進行臨床判斷的必要性。

由於科技的快速發展、醫療服務模式的變革以及公共衛生重點的調整，登革熱診斷技術正經歷重大變革。儘管準確快速的檢測仍然是有效臨床管理和疫情控制的基礎，但從血清學檢測到抗原檢測和分子診斷等多種檢測方法的存在，給臨床醫生、實驗室技術人員和採購經理帶來了複雜的決策環境。這就需要在臨床需求、操作限制和監管要求之間進行謹慎的權衡。

平台快速創新、檢測分散化以及不斷變化的法規正在重塑診斷路徑，並加速醫療保健系統採用這些方法。

過去五年標誌著登革熱檢測的研發、檢驗和實施方式發生了轉折。檢測化學和平台工程的進步提高了多種檢測方法的分析性能，加快了抗原檢測的反應速度，並提高了分子檢測的處理能力和自動化程度。同時，數位轉型將診斷儀器與實驗室資訊系統連接起來，實現了即時報告並整合到監控網路中。由此，一個響應更迅速的診斷生態系統得以構建，從而能夠更有效地支持疫情爆發檢測和臨床分診。

評估美國於 2025 年實施關稅對供應鏈調整、採購應對措施以及診斷藥物採購和營運的策略影響。

美國在2025年實施的新關稅為採購登革熱診斷組件和成品檢測套組的機構帶來了複雜的挑戰。這些關稅措施適用於進口設備、試劑和某些檢測套組組件，增加了從受影響地區採購特定產品的直接成本，迫使採購團隊重新評估籌資策略和總到岸成本。供應商和醫療系統正在採取措施，透過重新評估供應商組合、探索區域性生產替代方案以及重組分銷協議來減輕眼前的成本負擔。

基於深度細分的診斷見解，解釋了測試類型、技術、最終用戶、產品形式、安裝環境和檢體矩陣如何決定實施方案的選擇。

了解細分市場動態對於選擇合適的診斷策略和調整產品系列以滿足使用者需求至關重要。從檢測類型來看，抗體檢測、抗原檢測和分子檢測之間存在明顯的臨床和操作權衡。抗體檢測（分為IgG和IgM檢測）在先前接觸評估和血清流行病學調查中發揮重要作用。抗原檢測（包括NS1酵素免疫分析法和快速NS1檢測）憑藉其快速性，有助於早期發現。分子檢測，包括常規PCR和即時PCR，仍然是確診的標準方法，需要高分析靈敏度和基因型資訊。

美洲、歐洲、中東和非洲以及亞太地區的區域診斷重點和實施決定了我們的採購和部署策略。

區域趨勢影響診斷方法的優先排序、檢驗和採購，美洲、歐洲、中東和非洲以及亞太地區的實際情況各不相同。在美洲，由於檢查室網路完善且私部門積極參與，以集中式分子檢測為照護現場抗原檢測的混合模式較為適用。特定國家的法規結構為緊急使用和上市後監測提供了明確的途徑，使製造商能夠在展示實際應用效能的同時擴大分銷範圍。

診斷設備製造商如何調整產品系列、製造韌性和數位化能力，以提供綜合登革熱檢測解決方案並確保供應鏈安全？

登革熱診斷生態系統中的主要企業正透過產品開發、策略夥伴關係和對生產韌性的投資，滿足不斷變化的需求。擁有包括抗原、抗體和分子檢測在內的多元化產品組合的企業，能夠滿足多層次的臨床路徑需求，在臨床現場提供快速篩檢檢測，並在中心檢查室提供確診檢測。檢測開發商和儀器製造商之間的策略合作正在加速整合解決方案的交付，從而減輕最終用戶檢驗的負擔，並縮短臨床部署時間。

為診斷產業領導者提供切實可行的策略步驟，以加強供應鏈、加速照護現場創新，並透過整合數位連結來推動應用。

產業領導者應迅速調整產品開發、供應鏈策略和客戶參與，以適應登革熱診斷領域不斷變化的實際情況。首先，應優先考慮採購管道多元化，並探索區域製造夥伴關係，以降低關稅造成的成本波動風險，並縮短關鍵試劑和儀器組件的前置作業時間。投資於靈活的生產合約和雙重籌資策略可確保供應連續性，並增強供應商的議價能力。其次，應加快開發並向市場推出與領先品牌相容的照護現場抗原檢測和側向層析檢測產品，以滿足快速分流和分散式監測的需求，同時保留用於確診和基因分型的實驗室級分子檢測方案。

採用嚴謹的混合方法研究途徑，結合專家訪談、檢查室檢驗審查、監管分析和供應鏈映射，得出以營運為中心的見解。

本研究採用結構化的混合方法整合證據，結合了定性專家訪談、檢查室檢驗審查、監管指南分析以及對同行評審文獻和技術白皮書的系統性回顧。主要工作包括透過與臨床實驗室技術人員、感染疾病專家、採購經理和診斷試劑開發人員對話，收集關於檢測性能、操作限制和實施注意事項的實際觀點。檢查室檢驗審查檢驗了抗體、抗原和分子診斷類別中代表性檢測的分析靈敏度、特異性和操作特性，重點關注檢體基質的適用性和儀器要求。

對診斷技術創新、營運完整性和供應鏈韌性進行最終綜合分析，以確定有效的登革熱檢測策略和專案優先事項。

技術創新、去中心化和供應鏈重組的整合，為登革熱診斷帶來了機會和營運挑戰。快速抗原檢測和改進的側向層析檢測方法提高了臨床及時發現病例的能力。同時，PCR設備和檢查室自動化技術的進步，使得集中式確診檢測和基因分型監測仍然不可或缺。此外，貿易政策的變化等外部因素，也使得供應鏈韌性和籌資策略成為決定採購風險和專案連續性的關鍵因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 登革熱檢測市場（依檢測類型分類）

  • 抗體檢測
    • IgG抗體檢測
    • IgM抗體檢測
  • 抗原檢測
    • Ns1酵素免疫分析法
    • NS1快速偵測
  • 分子檢測
    • 常規聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應

第9章：登革熱檢測市場：依技術分類

  • 酵素免疫分析法
  • 側向流動免疫檢測
    • 膠體金法
    • 螢光免疫分析
  • 微陣列技術
  • 聚合酵素鏈鎖反應
    • 常規聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應

第10章：登革熱偵測市場：依最終用戶分類

  • 診所
  • 診斷檢查室
  • 醫院
  • 研究機構

第11章 登革熱檢測市場：依產品類型分類

  • 裝置
    • 領導者
    • 聚合酵素連鎖反應熱迴圈儀
  • 軟體解決方案
  • 檢測套組

第12章：登革熱檢測市場（按地區分類）

  • 中心檢查室
  • 照護端

第13章 登革熱偵測市場（依檢體類型分類）

  • 電漿
  • 血清
  • 全血

第14章 登革熱檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：登革熱檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 登革熱檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國登革熱檢測市場

第18章：中國登革熱檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alpine Biomedicals Pvt Ltd.
  • Bio-Rad Laboratories, Inc.
  • Chembio Diagnostics, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Meridian Bioscience, Inc.
  • MNP Meditech Pvt. Ltd.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0E5

The Dengue Testing Market was valued at USD 558.61 million in 2025 and is projected to grow to USD 599.01 million in 2026, with a CAGR of 6.27%, reaching USD 855.12 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 558.61 million
Estimated Year [2026] USD 599.01 million
Forecast Year [2032] USD 855.12 million
CAGR (%) 6.27%

Introducing the current dengue diagnostics environment with evolving assay modalities, deployment challenges, and clinical decision imperatives across care settings

Dengue diagnostic capabilities are at a pivotal juncture, shaped by rapid technological progress, shifting care delivery models, and evolving public health priorities. Accurate and timely detection remains foundational to effective clinical management and outbreak control, while the diversity of available assays-from serology to antigen detection to molecular methods-creates a complex decision environment for clinicians, laboratorians, and procurement leaders. The landscape demands careful calibration between clinical needs, operational constraints, and regulatory expectations.

Historically, laboratory-based molecular platforms provided the highest analytical sensitivity, contrasted with point-of-care antigen assays that emphasized speed and simplicity. However, these distinctions are blurring as innovations in lateral flow chemistry, microarray platforms, and real-time polymerase chain reaction instruments narrow gaps in performance, cost per test, and deployment flexibility. In parallel, the global push toward decentralized testing and stronger surveillance has increased demand for assays validated on a range of sample types including plasma, serum, and whole blood, and for solutions that integrate with electronic health systems to enable case reporting and epidemiological monitoring.

Against this backdrop, stakeholders must balance clinical performance metrics such as sensitivity, specificity, and window-of-detection with pragmatic considerations including throughput, cold-chain requirements, and training needs at clinics and point-of-care settings. As dengue continues to circulate in endemic and newly exposed regions, the capacity to choose and implement diagnostics that align with local laboratory infrastructure and patient pathways will be a defining factor in limiting morbidity and optimizing resource use.

How rapid platform innovation, decentralization of testing, and regulatory evolution are reshaping diagnostic pathways and accelerating adoption across healthcare systems

The past five years have seen transformative shifts that are redefining how dengue testing is developed, validated, and delivered. Advances in assay chemistry and platform engineering have lifted analytical performance across multiple categories, enabling antigen tests with faster time-to-result and molecular tests with greater throughput and automation. These technology improvements are being accompanied by digital transformations that connect diagnostic devices to laboratory information systems, enabling real-time reporting and integration into surveillance networks. The result is a more responsive diagnostic ecosystem that can better support outbreak detection and clinical triage.

Simultaneously, there has been a marked movement toward decentralization of testing. Point-of-care settings and outpatient clinics are increasingly equipped to perform rapid antigen and antibody assays, facilitated by simpler workflows and lower training requirements. This shift is complemented by investments in portable PCR instruments and reader devices that allow molecular-level confirmation closer to the patient. As a consequence, healthcare systems are re-evaluating diagnostic algorithms to balance the use of rapid screening assays with confirmatory molecular testing, optimizing resource allocation while preserving diagnostic confidence.

Market dynamics have also been influenced by new regulatory pathways and emphasis on real-world performance data. Health authorities are leaning on post-market surveillance and conditional approvals that prioritize timely access without sacrificing reliability. In parallel, strategic partnerships among diagnostics manufacturers, academic groups, and public health agencies are accelerating validation studies, enabling faster adoption of innovative assays. Taken together, these changes are driving a more agile, connected, and clinically integrated approach to dengue testing that prioritizes speed, accuracy, and operational fit.

Assessing the 2025 United States tariff-induced supply chain adjustments, procurement responses, and strategic implications for diagnostic sourcing and operations

The introduction of new tariffs in the United States in 2025 has introduced a layer of complexity for organizations procuring dengue diagnostic components and finished assays. Tariff measures applied to imported instruments, reagents, and certain assay components have increased the direct cost of sourcing specific items from affected jurisdictions, prompting procurement teams to re-assess sourcing strategies and total landed cost. Suppliers and health systems have responded by reevaluating supplier portfolios, seeking regional manufacturing alternatives, and restructuring distribution agreements to mitigate immediate cost exposure.

Beyond procurement cost pressures, the tariff environment has influenced supply chain design and inventory management. Organizations with limited domestic supply options have increased safety stock levels and extended planning horizons to buffer against import cost volatility and potential lead-time increases. Suppliers have accelerated efforts to localize production of critical inputs, including readers and thermal cyclers, as well as key consumables and reagents, though such initiatives require capital investment and time to realize. In the interim, some buyers have negotiated longer-term contracts to secure supply at predictable prices, while others have diversified their supplier base to distribute risk.

The tariff-driven reconfiguration has also affected competitive dynamics. Manufacturers with vertically integrated supply chains or local production footprints are gaining relative advantage, as they can offer more stable pricing and shorter lead times. Conversely, smaller suppliers reliant on cross-border sourcing face pressure to justify pricing and demonstrate continuity of supply. Public health programs and hospitals operating under constrained budgets are particularly exposed to these shifts, prompting re-prioritization of procurement toward assays and platforms that deliver the most clinical utility per dollar and that minimize exposure to tariff-affected inputs.

Deep segmentation-driven diagnostic insights describing how test types, technologies, end users, product formats, settings, and sample matrices determine deployment choices

Understanding segmentation dynamics is essential to selecting appropriate diagnostic strategies and aligning product portfolios with user needs. When viewing the landscape through the lens of test type, there are clear clinical and operational trade-offs among antibody, antigen, and molecular options. Antibody testing, split into IgG and IgM assays, serves useful roles in retrospective exposure assessment and seroprevalence work, while antigen testing-comprising NS1 enzyme-linked immunosorbent assays and rapid NS1 tests-supports early detection with the benefit of speed. Molecular testing, including conventional PCR and real-time PCR approaches, remains the standard for confirmation where high analytical sensitivity and genotype information may be required.

Technological segmentation further influences adoption. Enzyme-linked immunosorbent assays continue to underpin high-throughput laboratory operations, whereas lateral flow immunoassays, differentiated by colloidal gold or fluorescent readouts, enable true point-of-care deployment with varying degrees of quantitative capacity. Microarray platforms add multiplexing capabilities that are valuable in differential diagnosis scenarios and in research settings, and polymerase chain reaction technologies, from conventional to real-time formats, provide the backbone for sensitive and specific viral detection that informs clinical decision-making and surveillance.

End-user considerations also drive product selection and implementation strategies. Clinics and point-of-care environments favor rapid, user-friendly formats with minimal instrument dependence; diagnostic laboratories emphasize assay reproducibility and throughput; hospitals balance the need for both rapid triage and confirmatory testing streams; and research institutes require platforms that support methodological flexibility and in-depth analyses. Product type segmentation highlights complementary commercial approaches: instruments and readers, which include thermal cyclers and digital readers, underpin platform-dependent assays; software solutions enable connectivity, data analytics, and results management; and test kits deliver the consumables required for routine testing operations. Finally, setting and sample type choices shape logistics and validation strategies, with central laboratories providing controlled environments that support complex workflows and point-of-care settings necessitating robustness across plasma, serum, and whole blood matrices. An integrated view across these segmentation dimensions reveals where investment in instrumentation, biochemical chemistry, and operational enablement will yield the greatest clinical and commercial returns.

Regional diagnostic priorities and implementation realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape procurement and deployment strategies

Regional dynamics shape how diagnostics are prioritized, validated, and procured, with distinct operational realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and considerable private-sector participation favor a mixed model of centralized molecular testing supplemented by point-of-care antigen testing in outpatient and emergency settings. Regulatory frameworks in certain countries provide clear pathways for emergency use and post-market surveillance, enabling manufacturers to scale distribution while demonstrating real-world performance.

Europe, the Middle East & Africa present a mosaic of adoption patterns influenced by national regulatory regimes and heterogeneous healthcare infrastructures. High-resource markets in Europe emphasize harmonized validation standards and integration with electronic health records, while markets across the Middle East and Africa often grapple with logistical constraints that drive demand for robust, low-maintenance assays and point-of-care platforms that tolerate variable cold-chain conditions. Collaborative procurement mechanisms and donor-supported initiatives play a meaningful role in driving access in lower-resource settings.

Asia-Pacific exhibits strong demand for both high-throughput laboratory solutions in metropolitan centers and rapid diagnostic options for decentralized clinics across endemic regions. Several countries in the region have developed local manufacturing capacity, which influences pricing and supply resiliency. Cross-border collaboration and regional surveillance networks have strengthened, fostering data sharing and harmonized response strategies. Taken together, these regional characteristics underline that diagnostic selection and deployment strategies must be tailored to local infrastructure, regulatory pathways, and epidemiological context to achieve effective case detection and public health impact.

How diagnostics companies are aligning product portfolios, manufacturing resilience, and digital capabilities to deliver integrated dengue testing solutions and secure supply chains

Leading firms and innovators in the dengue diagnostics ecosystem are responding to emergent needs through a combination of product development, strategic partnerships, and investments in manufacturing resilience. Companies with diversified portfolios that span antigen, antibody, and molecular offerings are positioned to meet multi-tiered clinical pathways, providing rapid screening at point-of-care and confirmatory testing in centralized laboratories. Strategic collaborations between assay developers and instrument manufacturers have accelerated the availability of integrated solutions that reduce validation burden for end users and shorten time-to-clinic deployment.

Commercial strategies increasingly emphasize connectivity features and software-enabled services that enhance the utility of diagnostic platforms. Companies that offer readers or thermal cyclers paired with secure data management systems enable laboratories and public health agencies to collect and analyze testing data more efficiently, improving case tracking and resource allocation. In addition, manufacturers that have invested in regional production or established distributed manufacturing partnerships are seeing tangible benefits in terms of supply continuity and responsiveness to tariff- or logistics-driven disruptions.

Innovation is also manifest in go-to-market approaches. Organizations that support end users through training, localized validation support, and bundled service agreements reduce implementation friction and build long-term adoption. Smaller specialized developers contribute to the ecosystem by delivering niche or high-performance assays that can be licensed or co-branded with larger platform providers. Collectively, these corporate behaviors underscore a shift toward integrated solutions that combine assay chemistry, hardware, and digital infrastructure to meet the practical demands of diverse healthcare environments.

Actionable strategic steps for diagnostics leaders to strengthen supply chains, accelerate point-of-care innovation, and integrate digital connectivity to drive adoption

Industry leaders should act decisively to align product development, supply chain strategy, and customer engagement with the evolving realities of dengue diagnostics. First, prioritize diversification of sourcing and consider regional manufacturing partnerships to reduce exposure to tariff-induced cost volatility and to shorten lead times for critical reagents and instrument components. Investing in flexible manufacturing contracts and dual-sourcing strategies will preserve continuity and create negotiating leverage with suppliers. Next, accelerate development and market readiness of point-of-care antigen and lateral flow formats with reader compatibility to meet demand for rapid triage and decentralized surveillance, while maintaining laboratory-grade molecular options for confirmatory testing and genotype analysis.

Leaders must also integrate digital enablement into product roadmaps. Embedding connectivity and standardized data export capabilities within instruments and readers will facilitate real-time case reporting, contribute to public health intelligence, and create value-added service opportunities. Concurrently, focus on end-user enablement by designing simplified workflows, providing comprehensive validation packages, and investing in training programs that reduce adoption friction. From a commercial perspective, offer flexible contracting models that account for procurement cycles in public health programs and hospitals, including outcome-oriented agreements and bundled solutions that combine instruments, consumables, and software services.

Finally, engage proactively with regulators and public health stakeholders to design validation studies that reflect real-world performance, including evaluations across plasma, serum, and whole blood, and in both central laboratory and point-of-care settings. Transparent post-market surveillance and robust real-world evidence generation will build trust and facilitate broader adoption. These combined actions will position companies to capture clinical relevance, maintain supply stability, and drive sustainable growth in an increasingly competitive and fragmented environment.

Rigorous mixed-methods research approach combining expert interviews, laboratory validation reviews, regulatory analyses, and supply chain mapping to produce operationally focused insights

This research synthesizes evidence from a structured, mixed-methods approach that combines qualitative expert interviews, laboratory validation reviews, regulatory guidance analyses, and a systematic review of peer-reviewed literature and technical white papers. Primary engagements included conversations with clinical laboratorians, infectious disease specialists, procurement leads, and diagnostic developers to capture frontline perspectives on assay performance, operational constraints, and deployment considerations. Laboratory validation reviews examined reported analytical sensitivity, specificity, and operational characteristics for representative assays across antibody, antigen, and molecular categories, with attention to sample matrix compatibility and instrument requirements.

Regulatory guidance and policy documents were analyzed to understand approval pathways, emergency use provisions, and post-market surveillance expectations that influence time-to-adoption. The methodology also incorporated supply chain mapping to identify sourcing dependencies for instruments, consumables, and reagents, and to assess potential exposure to tariff and logistics disruptions. Where possible, findings were triangulated across data streams to increase confidence in conclusions and to highlight areas where evidence is limited or variable.

Limitations inherent to the methodology include variability in the quality and availability of performance data across assay types and the rapidly evolving nature of regulatory decisions and supply chain conditions. To mitigate these limitations, the research prioritized primary stakeholder input and validated laboratory findings against multiple independent sources. The resulting analysis aims to provide an operationally useful synthesis rather than definitive technical validation, supporting decision-makers in planning implementation and procurement strategies that account for both clinical and logistical considerations.

Concluding synthesis of diagnostic innovation, operational alignment, and supply chain resilience that defines effective dengue testing strategies and program priorities

The convergence of technological innovation, decentralization, and supply chain realignment has created both opportunities and operational challenges for dengue diagnostics. Rapid antigen and improved lateral flow formats are expanding the capacity for timely case detection at the point of care, while advances in PCR instrumentation and laboratory automation sustain the need for centralized confirmatory testing and genotypic surveillance. At the same time, external forces such as trade policy shifts have made supply chain resilience and sourcing strategy primary determinants of procurement risk and program continuity.

For practitioners and decision-makers, the imperative is clear: align diagnostic selection with clinical pathways and operational realities. This requires a nuanced assessment of test type and technology trade-offs, deliberate sourcing strategies to mitigate external cost pressures, and investment in digital and training infrastructure that reduces implementation friction. Organizations that adopt an integrated approach-combining robust point-of-care screening, laboratory confirmation where needed, and data connectivity-will be best positioned to maintain diagnostic continuity and to support effective clinical and public health responses.

Looking ahead, continued collaboration among diagnostic developers, health systems, and regulatory authorities will be essential to translate innovation into accessible, reliable testing programs. Stakeholders who prioritize supply chain diversification, real-world performance validation, and user-centered product design will accelerate adoption and improve outcomes for patients and communities affected by dengue.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dengue Testing Market, by Test Type

  • 8.1. Antibody Test
    • 8.1.1. Igg Antibody Test
    • 8.1.2. Igm Antibody Test
  • 8.2. Antigen Test
    • 8.2.1. Ns1 Enzyme Linked Immunosorbent Assay
    • 8.2.2. Ns1 Rapid Test
  • 8.3. Molecular Test
    • 8.3.1. Conventional Polymerase Chain Reaction
    • 8.3.2. Real Time Polymerase Chain Reaction

9. Dengue Testing Market, by Technology

  • 9.1. Enzyme Linked Immunosorbent Assay
  • 9.2. Lateral Flow Immunoassay
    • 9.2.1. Colloidal Gold Assay
    • 9.2.2. Fluorescent Immunoassay
  • 9.3. Microarray Technology
  • 9.4. Polymerase Chain Reaction
    • 9.4.1. Conventional Polymerase Chain Reaction
    • 9.4.2. Real Time Polymerase Chain Reaction

10. Dengue Testing Market, by End User

  • 10.1. Clinics
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Dengue Testing Market, by Product Type

  • 11.1. Instruments
    • 11.1.1. Readers
    • 11.1.2. Thermal Cyclers
  • 11.2. Software Solutions
  • 11.3. Test Kits

12. Dengue Testing Market, by Setting

  • 12.1. Central Laboratory
  • 12.2. Point Of Care

13. Dengue Testing Market, by Sample Type

  • 13.1. Plasma
  • 13.2. Serum
  • 13.3. Whole Blood

14. Dengue Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Dengue Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Dengue Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Dengue Testing Market

18. China Dengue Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Alpine Biomedicals Pvt Ltd.
  • 19.7. Bio-Rad Laboratories, Inc.
  • 19.8. Chembio Diagnostics, Inc.
  • 19.9. Danaher Corporation
  • 19.10. F. Hoffmann-La Roche Ltd.
  • 19.11. Meridian Bioscience, Inc.
  • 19.12. MNP Meditech Pvt. Ltd.
  • 19.13. QIAGEN N.V.
  • 19.14. Siemens Healthineers AG
  • 19.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DENGUE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DENGUE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS DENGUE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL DENGUE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GCC DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 229. GCC DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 230. GCC DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 231. GCC DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. GCC DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 238. GCC DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. G7 DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 268. G7 DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 269. G7 DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 270. G7 DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 273. G7 DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. G7 DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. G7 DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. G7 DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 277. G7 DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. NATO DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. NATO DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 281. NATO DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 282. NATO DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 283. NATO DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. NATO DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. NATO DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 290. NATO DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)